Equities Analysts Set Expectations for Healthways Inc.’s Q1 2017 Earnings (HWAY)
Healthways Inc. (NASDAQ:HWAY) – Equities researchers at Oppenheimer Holdings dropped their Q1 2017 earnings estimates for shares of Healthways in a note issued to investors on Monday. Oppenheimer Holdings analyst M. Naidu now anticipates that the brokerage will post earnings of $0.36 per share for the quarter, down from their prior estimate of $0.37. Oppenheimer Holdings currently has a “Outperform” rating and a $27.00 price target on the stock. Oppenheimer Holdings also issued estimates for Healthways’ Q2 2017 earnings at $0.37 EPS and Q3 2017 earnings at $0.37 EPS.
Healthways (NASDAQ:HWAY) last posted its quarterly earnings data on Tuesday, November 1st. The company reported $0.30 EPS for the quarter, missing analysts’ consensus estimates of $0.52 by $0.22. Healthways had a positive return on equity of 13.49% and a negative net margin of 24.50%. The firm earned $125 million during the quarter, compared to analyst estimates of $124.71 million. During the same period in the prior year, the business posted $0.35 EPS. The company’s revenue for the quarter was up 10.1% on a year-over-year basis.
Several other equities research analysts also recently commented on HWAY. Zacks Investment Research raised shares of Healthways from a “hold” rating to a “buy” rating and set a $29.00 target price for the company in a research note on Wednesday, September 21st. Barrington Research reaffirmed an “outperform” rating and issued a $30.00 target price (up previously from $29.00) on shares of Healthways in a research note on Thursday, October 13th. FBR & Co upped their price target on shares of Healthways from $16.00 to $21.00 and gave the company an “outperform” rating in a report on Wednesday, August 10th. Barclays PLC upgraded shares of Healthways from an “underweight” rating to an “equal weight” rating and upped their price target for the company from $12.00 to $27.00 in a report on Monday, August 22nd. Finally, Jefferies Group set a $26.00 target price on shares of Healthways and gave the stock a “hold” rating in a report on Thursday, August 18th. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and four have given a buy rating to the stock. Healthways currently has an average rating of “Hold” and an average target price of $25.64.
Healthways (NASDAQ:HWAY) opened at 21.95 on Wednesday. The company has a 50-day moving average of $24.61 and a 200-day moving average of $18.25. The firm’s market cap is $828.59 million. Healthways has a 1-year low of $9.18 and a 1-year high of $27.30.
A number of institutional investors have recently added to or reduced their stakes in the company. Bank of Montreal Can raised its position in Healthways by 610.2% in the third quarter. Bank of Montreal Can now owns 4,403 shares of the company’s stock worth $116,000 after buying an additional 3,783 shares in the last quarter. KCG Holdings Inc. acquired a new position in Healthways during the third quarter worth approximately $216,000. Acrospire Investment Management LLC raised its position in Healthways by 80.9% in the second quarter. Acrospire Investment Management LLC now owns 9,612 shares of the company’s stock worth $111,000 after buying an additional 4,300 shares in the last quarter. Quantitative Systematic Strategies LLC acquired a new position in Healthways during the second quarter worth approximately $118,000. Finally, Profund Advisors LLC raised its position in Healthways by 4.5% in the second quarter. Profund Advisors LLC now owns 10,668 shares of the company’s stock worth $123,000 after buying an additional 456 shares in the last quarter. 95.37% of the stock is currently owned by institutional investors and hedge funds.
In related news, Director Mary Jane England sold 3,816 shares of the firm’s stock in a transaction dated Friday, August 26th. The shares were sold at an average price of $24.78, for a total transaction of $94,560.48. Following the transaction, the director now directly owns 39,068 shares of the company’s stock, valued at $968,105.04. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, CEO Donato Tramuto purchased 5,060 shares of the stock in a transaction that occurred on Friday, November 4th. The shares were acquired at an average cost of $19.95 per share, for a total transaction of $100,947.00. Following the completion of the transaction, the chief executive officer now owns 275,442 shares of the company’s stock, valued at approximately $5,495,067.90. The disclosure for this purchase can be found here. Corporate insiders own 14.01% of the company’s stock.
Healthways Company Profile
Healthways, Inc (Healthways) provides network delivered solutions and population health management services that are designed to help people manage their wellbeing, thereby managing their health and productivity, and their health-related costs. The Company operates in the domestic and international segments, which are collectively known as the well-being improvement services segment.
Receive News & Stock Ratings for Healthways Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Healthways Inc. and related stocks with our FREE daily email newsletter.